Morgan Stanley has recently filed a free writing prospectus detailing the terms for its new contingent income memory auto-callable securities. This innovative financial product aims to attract investors seeking unique investment opportunities in a fluctuating market.
These securities, which are due on November 29, 2029, are linked to Oracle Corporation's common stock (ORCL) and feature an automatic early redemption clause based on the performance of the underlying asset. This offering reflects Morgan Stanley's commitment to providing diverse investment options tailored to current market conditions.
Background
Morgan Stanley, incorporated in Delaware, operates within the Security Brokers, Dealers & Flotation Companies sector (SIC: 6211). The company trades on the New York Stock Exchange under the ticker symbol MS and several preferred shares. It has a long-standing reputation in the financial services industry, providing a wide range of investment banking, securities, wealth management, and investment management services.
What the Filing Says
The filing, dated November 12, 2026, outlines key features of the securities, including a contingent coupon rate between 18.00% to 19.00% per annum, and an estimated value of approximately $952.60 per security. The document emphasizes the necessity for investors to review accompanying materials for a comprehensive understanding of the investment risks involved.
Impact
This new offering may influence both retail and institutional investors looking for innovative products in the financial market. As a significant player in the security brokerage industry, Morgan Stanley's actions could prompt competitors to enhance or diversify their own product offerings to remain competitive in the evolving landscape.
What's Next
The filing does not specify any immediate next steps, but investors and analysts will likely monitor the performance of these securities closely as they become available in the market.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










